Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,691 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase.
Gomez R, Jolly S, Williams T, Tucker T, Tynebor R, Vacca J, McGaughey G, Lai MT, Felock P, Munshi V, DeStefano D, Touch S, Miller M, Yan Y, Sanchez R, Liang Y, Paton B, Wan BL, Anthony N. Gomez R, et al. Among authors: sanchez r. Bioorg Med Chem Lett. 2011 Dec 15;21(24):7344-50. doi: 10.1016/j.bmcl.2011.10.027. Epub 2011 Oct 17. Bioorg Med Chem Lett. 2011. PMID: 22071300
The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.
Tucker TJ, Saggar S, Sisko JT, Tynebor RM, Williams TM, Felock PJ, Flynn JA, Lai MT, Liang Y, McGaughey G, Liu M, Miller M, Moyer G, Munshi V, Perlow-Poehnelt R, Prasad S, Sanchez R, Torrent M, Vacca JP, Wan BL, Yan Y. Tucker TJ, et al. Among authors: sanchez r. Bioorg Med Chem Lett. 2008 May 1;18(9):2959-66. doi: 10.1016/j.bmcl.2008.03.064. Epub 2008 Mar 25. Bioorg Med Chem Lett. 2008. PMID: 18396399
Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
Tucker TJ, Sisko JT, Tynebor RM, Williams TM, Felock PJ, Flynn JA, Lai MT, Liang Y, McGaughey G, Liu M, Miller M, Moyer G, Munshi V, Perlow-Poehnelt R, Prasad S, Reid JC, Sanchez R, Torrent M, Vacca JP, Wan BL, Yan Y. Tucker TJ, et al. Among authors: sanchez r. J Med Chem. 2008 Oct 23;51(20):6503-11. doi: 10.1021/jm800856c. Epub 2008 Oct 1. J Med Chem. 2008. PMID: 18826204
Substituted tetrahydroquinolines as potent allosteric inhibitors of reverse transcriptase and its key mutants.
Su DS, Lim JJ, Tinney E, Wan BL, Young MB, Anderson KD, Rudd D, Munshi V, Bahnck C, Felock PJ, Lu M, Lai MT, Touch S, Moyer G, Distefano DJ, Flynn JA, Liang Y, Sanchez R, Prasad S, Yan Y, Perlow-Poehnelt R, Torrent M, Miller M, Vacca JP, Williams TM, Anthony NJ. Su DS, et al. Among authors: sanchez r. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5119-23. doi: 10.1016/j.bmcl.2009.07.031. Epub 2009 Jul 10. Bioorg Med Chem Lett. 2009. PMID: 19631528
Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
Su DS, Lim JJ, Tinney E, Wan BL, Young MB, Anderson KD, Rudd D, Munshi V, Bahnck C, Felock PJ, Lu M, Lai MT, Touch S, Moyer G, DiStefano DJ, Flynn JA, Liang Y, Sanchez R, Perlow-Poehnelt R, Miller M, Vacca JP, Williams TM, Anthony NJ. Su DS, et al. Among authors: sanchez r. J Med Chem. 2009 Nov 26;52(22):7163-9. doi: 10.1021/jm901230r. J Med Chem. 2009. PMID: 19883100
Biaryl ethers as potent allosteric inhibitors of reverse transcriptase and its key mutant viruses: aryl substituted pyrazole as a surrogate for the pyrazolopyridine motif.
Su DS, Lim JJ, Tinney E, Tucker TJ, Saggar S, Sisko JT, Wan BL, Young MB, Anderson KD, Rudd D, Munshi V, Bahnck C, Felock PJ, Lu M, Lai MT, Touch S, Moyer G, Distefano DJ, Flynn JA, Liang Y, Sanchez R, Perlow-Poehnelt R, Miller M, Vacca JP, Williams TM, Anthony NJ. Su DS, et al. Among authors: sanchez r. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4328-32. doi: 10.1016/j.bmcl.2010.06.083. Epub 2010 Jun 17. Bioorg Med Chem Lett. 2010. PMID: 20609585
Epsilon substituted lysinol derivatives as HIV-1 protease inhibitors.
Jones KL, Holloway MK, Su HP, Carroll SS, Burlein C, Touch S, DiStefano DJ, Sanchez RI, Williams TM, Vacca JP, Coburn CA. Jones KL, et al. Bioorg Med Chem Lett. 2010 Jul 15;20(14):4065-8. doi: 10.1016/j.bmcl.2010.05.082. Epub 2010 May 25. Bioorg Med Chem Lett. 2010. PMID: 20547452
Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors.
Greshock TJ, Sanders JM, Drolet RE, Rajapakse HA, Chang RK, Kim B, Rada VL, Tiscia HE, Su H, Lai MT, Sur SM, Sanchez RI, Bilodeau MT, Renger JJ, Kern JT, McCauley JA. Greshock TJ, et al. Bioorg Med Chem Lett. 2016 Jun 1;26(11):2631-5. doi: 10.1016/j.bmcl.2016.04.021. Epub 2016 Apr 9. Bioorg Med Chem Lett. 2016. PMID: 27106707
Strategies towards improving the pharmacokinetic profile of ε-substituted lysinol-derived HIV protease inhibitors.
Rajapakse HA, Walji AM, Moore KP, Zhu H, Mitra AW, Gregro AR, Tinney E, Burlein C, Touch S, Paton BL, Carroll SS, DiStefano DJ, Lai MT, Grobler JA, Sanchez RI, Williams TM, Vacca JP, Nantermet PG. Rajapakse HA, et al. Among authors: sanchez ri. ChemMedChem. 2011 Feb 7;6(2):253-7. doi: 10.1002/cmdc.201000395. Epub 2010 Dec 29. ChemMedChem. 2011. PMID: 21275047 No abstract available.
2,691 results